200 Lanreotide Injections: A Milestone in Long‑Term Neuroendocrine Tumour (NET) Management

Two hundred injections. It’s a milestone that carries weight — not because of the number itself, but because of what it represents: continuity, stability, and the lived reality of managing Neuroendocrine Cancer over the long term. Lanreotide has been part of my life since 2010, and today’s dose marks more than a treatment event — it marks a journey shaped by science, routine, and resilience.

What Lanreotide Does — and Why Deep‑Subcutaneous Matters

Lanreotide is a long‑acting somatostatin analogue designed to bind to SSTR2 on neuroendocrine tumour cells and reduce hormone secretion while slowing tumour proliferation. Its deep‑subcutaneous delivery is deliberate: the viscous gel forms a depot in the fat layer, releasing steadily over weeks. This isn’t a standard subcutaneous injection. It requires a specific needle length, a defined anatomical site, and a technique that ensures the depot sits where it should.

Guided Links:

• Somatostatin Analogues Explained
• Understanding Deep‑Subcutaneous Injection

The Lived Experience: Turning Treatment Into Rhythm

Long‑term SSA therapy shapes the the natural, rhythmic flow of daily existence for thousands of people with NETs with most people being treated once every 28 days.  Two hundred injections teaches you how your body responds, how to plan around injection days, how to manage the occasional sting or lump, and how to integrate treatment into normality.

This isn’t passive endurance — it’s active adaptation.

Guided Links:

• Lanreotide – It’s Calling the Shots
• At Home With Lanreotide

The Interval Reality — 28 Days, 21 Days, 14 Days

People often assume lanreotide is simply “once a month.” But the interval defines the lived experience.

• 28‑day rhythm — the standard cadence
• 21‑day interval — used when symptoms or markers need tighter control
• 14‑day interval — off‑label but clinically used in selected cases

Shorter intervals mean more frequent injections, more planning, and a tighter loop between doses.

Why This Milestone Matters for Advocacy

A 200‑injection milestone reflects the broader NET community experience. It highlights the chronic nature of NET management, the importance of access to long‑term therapy, and the emotional labour of sustained treatment.

Guided Links:

• Spotlight Series Index
• PRRT Overview

Looking Ahead — Stability as a Platform for Progress

Reaching 200 injections isn’t an ending — it’s a waypoint. It reflects how far NET care has come and how much is still evolving: alpha‑emitters, new radiopharmaceuticals, targeted biologicals, and next‑generation imaging.

I have no scientific evidence that I am still alive due to Lanreotide but when my Oncologist offered me two year surveillance intervals (something I ask to be deferred), I did ask why I am stable and why I have not had a recurrence, he suggested that perhaps long term use of somatostatin analogues has played a part.

As a stage IV small intestine NET with many distant metastases at diagnosis, long‑term lanreotide therapy has provided the stability to witness — and benefit from — that progress. 

BUT …… Milestones like this aren’t really about counting syringes. They’re about recognising the continuity that allows people with NETs to plan, advocate, and live fully.

Thanks for reading